Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.

"Conflict-of-interest disclosure: R.R. receives research funding from Crispr Therapeutics and Skyline Therapeutics; holds equity in and is cofounder of InnDura Therapeutics; and reports consultancy and serves on the scientific advisory board for Glycostem and xNK Therapeutics. J.K. reports serving on the scientific advisory board for Cugene and Mallinckrodt; consulting for Equilibrium, Gentbio, Cue biopharma, Biolojic Design, and Tr1X; and research for Amgen, Clinigen Laboratories, Bristol Myers Squibb, Miltenyi Biotec, Regeneron, and Equilibrium. The remaining authors declare no competing financial interests."

"J.A.F. received support from a Hematology Opportunities for the Next Generation of Research Scientists award from the American Society of Hematology."